Table 1:

Demographic, clinical, and MRI characteristics of patients

	Patients (n = 22)	Healthy Volunteers (n = 12)
Age^*^†	40.3 ± 8.8 (22−57) years	41.5 ± 11.2 (28−58) years
Gender^†	16 women; 6 men	6 women; 6 men
MS type	10 SPMS;12 RRMS
Disease duration^*	9.8 ± 8.2 (0.2−26.1) years
EDSS score^*	3.3 ± 1.9 (0−7.0) [baseline]
	3.4 ± 2.1 (0−6.5) [end]
Number of CELs^*	41.2 ± 82.9 (0−345) [total]
T2 lesions volume* (cm³)	16.2 ± 16.9 (1.2−68.2) [baseline]
	14.38 ± 15.2 (0.7−52.0) [end]
T1 BHs number^*	10.3 ± 8.9 (0−37) [baseline]
	10.5 ± 10.1 (0−39) [end]
T1 BHs volume^* (cm³)	1.8 ± 2.0 (0−7.5) [baseline]
	1.9 ± 2.3 (0−8.3) [end]
BPF^*^‡	0.80 ± 0.02 (0.76−0.83) [baseline]	0.85 ± 0.01 (0.84−0.88)
	0.79 ± 0.02 (0.74−0.83) [end]
On-going therapy	Cyclophoshamide = 1
(4 untreated patients)	Copolimer-1 = 4
	Interferon β (IFNβ) = 6
	IFNβ + Daclizumab = 7

Note:—MS indicates multiple sclerosis; RRMS, relapsing-remitting multiple sclerosis; SPMS, secondary-progressive multiple sclerosis; EDSS, expanded disability status scale; CEL, contrast-enhancing lesion; BH, black hole; BPF, brain parenchymal fraction.
* mean ± SD (range).
^† P values vs healthy volunteers > .05.
^‡ P ≤ .0001. See text for comparisons within patients at different time points.